Kurs & Likviditet
Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Informationsteknik |
| Industri | Programvara |
Aiforia Technologies Plc, Company release, March 27, 2024 at 11:30 a.m. EET
Share subscriptions based on stock options 2021 II
A total of 50,000 Aiforia Technologies Plc’s new shares has been subscribed for with the Stock Options 2021 II on March 4, 2024. For subscriptions made with the stock options 2021 II the entire subscription price of EUR 68,620.00 will be entered in the reserve for invested unrestricted equity.
After the trade registration the total amount of shares is 26,000,616.
The shares subscribed for under the stock options 2021 II have been registered in the Trade Register on March 27, 2024, as of which date the new shares will establish shareholder rights.
The shares will be traded in the Nasdaq Helsinki Plc’s First North Growth Market Finland -marketplace as an additional lot with the company’s old shares as of March 28, 2024.
The terms and conditions of stock options are available on the company's website at https://investors.aiforia.com/en/.
Further inquiries
Veli-Matti Parkkonen, CFO, Aiforia Technologies Plc
tel. +358 40 500 9878
https://investors.aiforia.com/
Certified Adviser
UB Corporate Finance Oy, tel. +358 9 25 380 225
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.
Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient.
Find out more at www.aiforia.com